Cyclacel Pharmaceuticals Stock Forecast, Price & News

-0.21 (-4.03 %)
(As of 08/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume65,724 shs
Average Volume371,154 shs
Market Capitalization$46.17 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CYCC News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Cyclacel Pharmaceuticals logo

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.84 out of 5 stars

Medical Sector

711th out of 1,309 stocks

Pharmaceutical Preparations Industry

354th out of 646 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Frequently Asked Questions

Is Cyclacel Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cyclacel Pharmaceuticals stock.
View analyst ratings for Cyclacel Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Cyclacel Pharmaceuticals?

Wall Street analysts have given Cyclacel Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cyclacel Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 796,400 shares, an increase of 22.1% from the June 15th total of 652,200 shares. Based on an average trading volume of 117,100 shares, the short-interest ratio is currently 6.8 days. Currently, 10.7% of the shares of the company are short sold.
View Cyclacel Pharmaceuticals' Short Interest

When is Cyclacel Pharmaceuticals' next earnings date?

Cyclacel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Cyclacel Pharmaceuticals

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) posted its earnings results on Wednesday, May, 12th. The biotechnology company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by $0.05.
View Cyclacel Pharmaceuticals' earnings history

How has Cyclacel Pharmaceuticals' stock been impacted by COVID-19?

Cyclacel Pharmaceuticals' stock was trading at $0.5399 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CYCC stock has increased by 826.1% and is now trading at $5.00.
View which stocks have been most impacted by COVID-19

When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work?

Cyclacel Pharmaceuticals shares reverse split before market open on Wednesday, April 15th 2020. The 1-20 reverse split was announced on Tuesday, April 14th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 14th 2020. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for CYCC?

1 Wall Street analysts have issued 12 month target prices for Cyclacel Pharmaceuticals' stock. Their forecasts range from $17.00 to $17.00. On average, they expect Cyclacel Pharmaceuticals' share price to reach $17.00 in the next year. This suggests a possible upside of 240.0% from the stock's current price.
View analysts' price targets for Cyclacel Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Cyclacel Pharmaceuticals' key executives?

Cyclacel Pharmaceuticals' management team includes the following people:
  • Mr. Spiro George Rombotis, Pres, CEO & Exec. Director (Age 62, Pay $772.64k)
  • Mr. Paul McBarron, Exec. VP of Fin., CFO, COO, Sec. & Exec. Director (Age 60, Pay $391.91k)
  • Dr. Mark H. Kirschbaum M.D., Sr. VP & Chief Medical Officer (Age 60, Pay $354.73k)
  • Ms. Gill Christie, Director of HR (Age 64)
  • Dr. Robert Westwood Ph.D., Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel. (Age 77)

What is Spiro Rombotis' approval rating as Cyclacel Pharmaceuticals' CEO?

1 employees have rated Cyclacel Pharmaceuticals CEO Spiro Rombotis on Spiro Rombotis has an approval rating of 100% among Cyclacel Pharmaceuticals' employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Cyclacel Pharmaceuticals' key competitors?

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA).

What is Cyclacel Pharmaceuticals' stock symbol?

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

Who are Cyclacel Pharmaceuticals' major shareholders?

Cyclacel Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include NEXT Financial Group Inc (0.09%).
View institutional ownership trends for Cyclacel Pharmaceuticals

Which major investors are buying Cyclacel Pharmaceuticals stock?

CYCC stock was bought by a variety of institutional investors in the last quarter, including NEXT Financial Group Inc.
View insider buying and selling activity for Cyclacel Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cyclacel Pharmaceuticals' stock price today?

One share of CYCC stock can currently be purchased for approximately $5.00.

How much money does Cyclacel Pharmaceuticals make?

Cyclacel Pharmaceuticals has a market capitalization of $46.17 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-8,440,000.00 in net income (profit) each year or ($3.87) on an earnings per share basis.

How many employees does Cyclacel Pharmaceuticals have?

Cyclacel Pharmaceuticals employs 12 workers across the globe.

What is Cyclacel Pharmaceuticals' official website?

The official website for Cyclacel Pharmaceuticals is

Where are Cyclacel Pharmaceuticals' headquarters?

Cyclacel Pharmaceuticals is headquartered at 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922.

How can I contact Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company can be reached via phone at 908-517-7330 or via email at [email protected]

This page was last updated on 8/3/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.